CRIS Stock — Curis Inc.: Cash, EV, Pipeline

What they do

We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.59

Market cap

$4.0M

Cash

$9.9M

Enterprise value

-$5.9M

Balance sheet

Cash	$9.9M
Debt	$0.0M
Net cash	$9.9M
Enterprise value	-$5.9M
Basic shares	2.1M shares
Fully diluted shares	7.1M shares
Fully diluted market cap	$4.2M
Cash per share	$4.72
Quarterly burn	$9.6M
Cash runway	1.0 quarters

Cash figures as of 2026-08-14. Database snapshot: 2026-11-11.

Share structure

Common

2.1M

Pre-funded warrants

0.2M

Options

0.1M

RSUs

0.0M

Warrants

4.7M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

7.1M

Cap table as of 2026-06-30.

Price history

Loading CRIS daily closes…

Loading price history…

Next catalyst

Emavusertib · Dec 1-31 · guided in 20d

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDDec 1-31 in 20d	Emavusertib TakeAim CLL Phase 2 of emavusertib in combination with zanubrutinib · NCT07271667	Phase 2	Not disclosed	December 2026
Dec 13, 2027 - Jan 24, 2028 in 13 mo	Emavusertib	Phase 2	Chronic Lymphocytic Leukemia; B-cell Malignancies	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Emavusertib

Phase 2 · Active Modality: small molecule (oral)

Aliases CA-4948

Target IRAK4 and FLT3

Partnerships Aurigene Discovery Technologies: exclusive license to emavusertib (2015 collaboration)

Indications

relapsed/refractory primary CNS lymphoma (PCNSL), with ibrutinib (Phase 2)
chronic lymphocytic leukemia (frontline), with zanubrutinib (Phase 2)
acute myeloid leukemia (AML) (Stage not disclosed)

Status note TakeAim Lymphoma Phase 1/2 (CA-4948-101, +ibrutinib) in R/R PCNSL: CHMP and FDA meetings March 2025 supported a potential accelerated path (EU conditional marketing authorization / US NDA on single-arm data). TakeAim CLL Phase 2 (CA-4948-203, +zanubrutinib): dosing began July 2026. AML monotherapy/combination studies substantially complete; further AML development contingent on additional funding. Orphan Drug Designation: FDA for PCNSL/AML/MDS; EC for PCNSL. January 2026 restructuring narrowed focus to PCNSL + CLL.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Emavusertib
Lead indication	Relapsed Hematologic Malignancy
Lead phase	Phase 2
Active trials	2
Collaborator trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07271667	Phase 2	Recruiting	Sponsor	CRIS	—	Chronic Lymphocytic Leukemia; B-cell Malignancies	December 2026
NCT03328078	Phase 2	Recruiting	Sponsor	CRIS	—	Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy; Relapsed Primary Central Nervous System Lymphoma	—
NCT05187182	Phase 1	Recruiting	Collaborator	Washington University School of Medicine	—	Gastric Cancer; Esophageal Cancer; Stomach Cancer	—
NCT07107750	Phase 1	Recruiting	Collaborator	Washington University School of Medicine	—	Metastatic Biliary Tract Cancer; Metastatic Biliary Tract Carcinoma	—
NCT03893487	Early Phase 1	Active, not recruiting	Collaborator	Sabine Mueller, MD, PhD	—	Diffuse Intrinsic Pontine Glioma; Recurrent Anaplastic Astrocytoma; Recurrent Glioblastoma	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Curis, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Stonepine Capital	3,312,185	-414,221	1.32%	2026-08-17
Sphera Biotech	98,996	-1,895,941	0.15%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CRIS — Curis Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

CRIS — Curis Inc.